Document Detail

A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.
MedLine Citation:
PMID:  23320990     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Topotecan was initially approved for the treatment of recurrent ovarian cancer. In cervical cancer, it has been investigated for its potential as part of systemic therapy for advanced and/or recurrent disease and in combination with cisplatin and radiation as a first-line treatment for advanced disease. As a topoisomerase I (topo I) inhibitor, its activity is predicted to be schedule-dependent and potentiated in a schedule-dependent manner by its interaction with DNA damaging agents.
AREAS COVERED: The cytotoxicity of topotecan is believed to be due to double-stranded DNA damage produced when the DNA replication 'fork' on the opposing DNA strand is interrupted by the ternary complex formed by topotecan, topoisomerase I and DNA. This review focuses on: i) combination studies of cisplatin + topotecan both as neoadjuvant and with concomitant radiation; ii) adding this drug as a radiosensitizer in pilot studies for locally advanced disease and iii) topotecan as part of non-cisplatin combinations in metastatic disease.
EXPERT OPINION: Cervical cancer continues to claim many victims among parts of the world where early detection and/or vaccination programs are not systemically applied. Topotecan is an attractive building block for improving therapy against advanced disease.
Fernanda Musa; Stephanie Blank; Franco Muggia
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-10-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  215-24     Citation Subset:  IM    
NYU Langone Medical Center, Department of Obstetrics and Gynecology, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic / methods,  trends
Drug Evaluation, Preclinical / methods,  trends
Topoisomerase I Inhibitors / pharmacokinetics*,  therapeutic use
Topotecan / pharmacokinetics*,  therapeutic use
Uterine Cervical Neoplasms / drug therapy*,  metabolism*
Reg. No./Substance:
0/Topoisomerase I Inhibitors; 123948-87-8/Topotecan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safet...
Next Document:  Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation preval...